Neue Aspekte in der Behandlung des Morbus Parkinson

Literatur

• 1 Parkinson Study Group . A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.  Arch Neurol. 2002;  59 1937-1943
• 2 Calker D van, Muller M, Hamprecht B. Adenosine regulates via two different types of receptors: the accumulation of cyclic AMP in cultured brain cells.  J Neurochem. 1979;  33 999-1005
• 3 Hubble J P, Hauser R. A novel adenosine antagonist (KW-6002) as a treatment for advanced Parkinson's disease with motor complications. In: The 54^th Annual Meeting of the American Academy of Neurology. Denver, Colorado; Neurology 2002
• 4 Sherzai A. et al .Adenosine A2a antagonist treatment of Parkinson's disease. In: The 54^th Annual Meeting of the American Academy of Neurology. Denver, Colorado; Neurology 2002
• 5 Petzer J P. et al . Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.  Bioorg Med Chem. 2003;  11 1299-1310
• 6 Maswood N. et al . Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys.  Neurobiol Aging. 2002;  23 881-889
• 7 Grondin R. et al . Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys.  J Neurosci. 2003;  23 1974-1980
• 8 Grondin R. et al . Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.  Brain. 2002;  125 2191-2201
• 9 Nutt J G. et al . Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.  Neurology. 2003;  60 69-73
• 10 Schwid S R. and the Parkinson Study Group . CEP-1347 in Parkinson's disease: A pilot study.  Mov Disord. 2002;  17, Suppl 5 P259